Here is a summary of health news briefs.
China says it will help key industries return to work in locked-down Shanghai
China said on Friday it would help hundreds of companies in key sectors resume production in Shanghai, the commercial capital at the center of the country’s latest COVID-19 outbreak, as companies warn of the cost growing economic restrictions. The announcement comes as a growing number of business leaders and analysts warn that China’s strict “zero-COVID” policy is triggering economic disruptions that ripple through global supply chains for goods, from electric vehicles to iPhones.
‘Final tweaks’ to COVID IP waiver agreement – WTO chief
The head of the World Trade Organization told Reuters on Thursday that negotiations on an intellectual property agreement for COVID-19 vaccines were underway between the four parties, saying they were seeking to agree on final terms. of the proposal. Since the draft compromise first appeared in the media a month ago, pressure has grown from civil society groups for the parties – the United States, European Union, India and South Africa – withdraw from the agreement. Other public figures have also criticized him, such as German Chancellor Olaf Scholz and former UN Secretary-General Ban Ki-moon, saying he focused too narrowly on vaccines.
More Chinese cities are tightening controls as Shanghai’s COVID cases rise
Shanghai reported a record number of symptomatic COVID-19 cases on Saturday and other parts of China tightened controls as the country maintained its “dynamic clearance” approach that aims to eradicate the highly transmissible variant of Omicron. Zhengzhou Airport Economic Zone, a manufacturing area in central China that includes Apple Inc supplier Foxconn, announced a 14-day lockdown on Friday “to be adjusted according to the epidemic situation.”
Omicron-specific Sinopharm and Sinovac vaccine candidates cleared for clinical trial
Candidate COVID-19 vaccines developed by a subsidiary of Sinopharm and Sinovac Biotech to target the Omicron variant have been approved for clinical trials in Hong Kong, the companies announced on Saturday. Scientists around the world are racing to study improved injections against Omicron, as data indicate that antibodies produced by vaccines based on older strains show lower activity in neutralizing the highly transmissible variant.
Growing disregard for COVID restrictions in China leads to wave of arrests
Sun Jian, a 37-year-old master’s student in the Chinese city of Yantai, has for months staged a solo campaign against his university’s COVID-19 prevention measures, including fierce criticism on social media. The straw that broke the camel’s back for authorities came on March 27, when Sun walked around his campus with a sign reading “lift the lockdown on Ludong.”
Nektar halts clinical trials of key cancer drug and shares plummet
Nektar Therapeutics said on Thursday it had halted all trials involving its key cancer drug following its failure in several studies, sending the drug developer’s stock down 23% in aftermarket trading. The trials Nektar stopped included those involving a combination of its drug bempegaldesleukin with Bristol Myers Squibb Co’s cancer drug Opdivo as well as Merck & Co Inc’s cancer drug Keytruda.
(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)